Beyond doublet chemotherapy for advanced non-small-cell lung cancer: Combination of targeted agents with first-line chemotherapy

Clinical Lung Cancer

Volumn 10, Issue 1, 2009, Pages 20-27

  Herbst, Roy S ^a   Lynch, Thomas J ^b   Sandler, Alan B ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor; Farnesyltransferase inhibitors; Protein kinase C; Tyrosine kinase

Indexed keywords

APRINOCARSEN; BEVACIZUMAB; BEXAROTENE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETALOCIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; LAPATINIB; LOMUSTINE; LONAFARNIB; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PRINOMASTAT; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINDESINE;

ACNE; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOMAGNESEMIA; INFUSION REACTION; INFUSION RELATED REACTION; LEUKOPENIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL TOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SKIN TOXICITY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VOMITING;

EID: 62549110421     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.003     Document Type: Review

References (91)

1. Vokes EE, Bitran JD. Non-small-cell lung cancer. Toward the next plateau. Chest 1994; 106:659-61.
2. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986; 4:14-22.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909.
4. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-41.
5. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17:3188-94.
6. Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991; 9:1453-61.
7. Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamide- mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:794-800.
8. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 59:828-36.
9. Shanafelt TD, Loprinzi C, Marks R, et al. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004; 22:1966-74.
10. Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006; 51:335-45.
11. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-30.
12. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005; 23:8380-8.
13. Georgoulias V, Ardavanis A, Agelidou A, et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 2004; 22:2602-9.
14. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360-7.
15. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
16. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005; 23:190-6.
17. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003; 21:3909-17.
18. Verma RP, Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem 2007; 15:2223-68.
19. Przybylo JA, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at snail's pace. Int J Biochem Cell Biol 2007; 39:1082-8.
20. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005; 23:2831-9.
21. Bissett D, O'Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005; 23:842-9.
22. Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:307a.
23. Shalinsky DR, Brekken J, Zou H, et al. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin Cancer Res 1999; 5:1905-17.
24. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999; 878:236-70.
25. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002; 29:78-86.
26. Hande KR, Collier M, Paradiso L, et al. Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin Cancer Res 2004; 10:909-15.
27. Lynch TJ, Raju R, Lind M, et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report. Proc Am Soc Clin Oncol 2003; 22 (Abstract 2504).
28. Paz-Ares L, Douillard J, Koralewski P, et al. Randomized phase III trial of gemcitabine/cisplatin (GC) and protein kinase C a (PKCa) antisense oligonucleotide aprinocarsen in patients (pts) with advanced stage non-small cell lung cancer (NSCLC). J Clin Oncol 2005; 23 (Abstract 7053).
29. Jassem J, Zatloukal P, Ramlau R, et al. A randomized phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2005; 23(16 suppl):627s (Abstract 7024).
30. Blumenschein GR, Khuri F, Gatzemeier U, et al. A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2005; 23(16 suppl):621s (Abstract 7001).
31. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50.
32. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007; 25(18 suppl):388s (Abstract LBA7514).
33. Lynch T, Patel T, Dreisbach L, et al. A randomized multicenter phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC)(B3-03). Presented at: the 12th World Conference on Lung Cancer; September 2-6, 2007; Seoul, Korea.
34. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Amer Soc Clin Oncol 2004; 23:617 (Abstract 7010).
35. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-84.
36. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22:785-94.
37. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-9.
38. Schering-Plough [Web site]. Schering-Plough discontinues phase III clinical study of Sarasar(TM) (lonafarnib) in non-small-cell lung cancer. Available at: http://www.schering-plough.com/schering-plough/news/release.jsp? releaseID=492402. Accessed: February 20, 2008.
39. Manegold C, von Pawel J, Zatloukal P, et al. A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Presented at: 2008 European Society for Medical Oncology conference; September 12-16, 2008; Stockholm, Sweden. Abstract LBA1.
40. Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(15 suppl):6s (Abstract 3).
41. Bristol-Myers Squibb Pharmaceutical Research Institute Investigator Brochure - Matrix metalloproteinase inhibitor BMS-275291, version 4. Wallingford (CT): Bristol-Myers Squibb; 2002.
42. Douillard JY, Peschel C, Shepherd F, et al. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2004; 46:361-8.
43. Tortora G, Ciardiello F. Antisense strategies targeting protein kinase C: preclinical and clinical development. Semin Oncol 2003; 30:26-31.
44. Lahn M, Su C, Li S, et al. Expression levels of protein kinase C-alpha in non-small-cell lung cancer. Clin Lung Cancer 2004; 6:184-9.
45. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682-9.
46. Caponigro F, Casale M, Bryce J. Farnesyl transferase inhibitors in clinical development. Expert Opin Investig Drugs 2003; 12:943-54.
47. Shi B, Yaremko B, Hajian G, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000; 46:387-93.
48. Adjei AA, Davis JN, Bruzek LM, et al. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 2001; 7:1438-45.
49. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102:37-46.
50. Thatcher N. Integrating new targeted agents into the treatment of non-small-cell lung cancer. Lung Cancer 2006; 54(suppl 2):S25-S31.
51. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial) [corrected]. J Clin Oncol 2003; 21:2237-46.
52. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-58.
53. Tarceva [package insert]. South San Francisco (CA): Genentech, Inc; 2007.
54. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
55. Erbitux [package insert]. Princeton (NJ): Bristol-Myers Squibb Company; 2007.
56. Butts CA, Bodkin D, Middleman EL, et al. Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):394s (Abstract 7539).
57. Herbst RS, Chansky K, Kelly K, et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. J Clin Oncol 2007; 25(18 suppl):395s (Abstract 7545).
58. Von Pawel J, Park K, Pereira JR, et al. Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX). J Clin Oncol 2006; 24(18 suppl):391s (Abstract 7109).
59. Rigas JR, Dragnev KH. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 2005; 10:22-33.
60. Toma S, Raffo P, Isnardi L, et al. Retinoids in lung cancer chemoprevention and treatment. Ann Oncol 1999; 10(suppl):S95-S102.
61. Brabender J, Danenberg KD, Metzger R, et al. The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res 2002; 8:438-43.
62. Xu XC, Sozzi G, Lee JS, et al. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst 1997; 89:624-9.
63. Boehm MF, Zhang L, Badea BA, et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994; 37:2930-41.
64. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
65. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76.
66. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2:667-73.
67. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65:671-80.
68. Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996; 93:14765-70.
69. Gossmann A, Helbich TH, Kuriyama N, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002; 15:233-40.
70. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
71. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88:1979-86.
72. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-91.
73. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34.
74. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12:426-37.
75. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113:1522.
76. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-24.
77. Herbst RS, Heymach JV, O'Reilly MS, et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007; 16:239-49.
78. Heymach J, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25 (Abstract 7544).
79. Tykerb [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2007.
80. Smylie M, Blumenschein GR, Dowlati A, et al. A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history. J Clin Oncol 2007; 25(18 suppl):412s (Abstract 7611).
81. Jackson WT, Froelich LL, Boyd RJ, et al. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies. J Pharmacol Exp Ther 1999; 288:286-94.
82. Janne PA, Paz-Ares RL, Gottfried M, et al. Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosanoid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma. J Clin Oncol 2006; 24(18 suppl):370s (Abstract 7024).
83. Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005; 11:2244-51.
84. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
85. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
86. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:839-44.
87. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:3908-14.
88. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6:273-86.
89. Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006; 7:741-6.
90. Rothenberg ML, Abbruzzese JL, Moore M, et al. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 1996; 78:627-32.
91. Avastin [package insert]. South San Francisco (CA): Genentech, Inc; 2007.